Azoles therapeutic drug monitoring and fungal antimicrobial resistance in adults with Cystic Fibrosis Source: International Congress 2018 – Latest developments in cystic fibrosis Year: 2018
Influence of the lung microbiome on antibiotic susceptibility of cystic fibrosis pathogens Source: Eur Respir Rev, 28 (152) 190041; 10.1183/16000617.0041-2019 Year: 2019
Anaerobic bacteria and host defence in cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Managing antimicrobial resistance in cystic fibrosis Source: International Congress 2014 – ERS/Lancet and Lancet Respiratory Medicine joint session: complicating infections in respiratory disease and critical care Year: 2014
Temporal progression of fungal microbiota in patients with cystic fibrosis Source: International Congress 2015 – Cystic fibrosis: assessment and treatment Year: 2015
Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Emerging pathogens in cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=66 Year: 2006
Emerging pathogens in cystic fibrosis Source: International Congress 2019 – State of the art session: Paediatric respiratory diseases Year: 2019
Cystic fibrosis microbiology, emerging pathogens and more treatment options Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children Year: 2018
Antiviral activity of azithromycin in cystic fibrosis airway epithelial cells Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Current concepts: host–pathogen interactions in cystic fibrosis airways disease Source: Eur Respir Rev 2014; 23: 320-332 Year: 2014
Novel antiviral properties of vitamin D in cystic fibrosis airway epithelial cells Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Antimicrobial peptides in the real world: implications for cystic fibrosis Source: Eur Respir J 2007; 29: 617-618 Year: 2007
Role of the microbiome and antibiotic therapy in IPF Source: Virtual Congress 2021 – Highlights from the JAMA Network on idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and lung cancer screening Year: 2021
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Host specificity of pseudomonas aeruginosa isolates from patients with cystic fibrosis and patients from different clinical backgrounds Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014
The characteristics of the minimum inhibitory concentration of antibiotics on pulmonary infections in patients with cystic fibrosis Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015
Neutrophil elastase-activated host defence peptide prodrugs kill pseudomonas aeruginosa in a cystic fibrosis lung milieu Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014
Formulation of dual modality nanoparticles to enhance tobramycin efficacy in cystic fibrosis Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013